Pharmaceuticals

Global Stelara (Ustekinumab) Market Report 2026–2035: Key Forecasts and Growth Areas

March 6, 2026March 9, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the stelara (ustekinumab) market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Stelara (Ustekinumab) Market expected to grow between 2026 and 2030?

The market size for stelara (ustekinumab) has experienced substantial growth in recent years. This market is expected to expand from $11.85 million in 2025 to $12.54 million in 2026, at a compound annual growth rate (CAGR) of 5.9%. Historically, this growth can be attributed to factors such as the limitations of conventional immunosuppressants, the increasing prevalence of autoimmune diseases, robust clinical efficacy data, hospital-based biologic administration, and the demand for durable remission.

The market for stelara (ustekinumab) is projected to experience robust expansion over the coming years, with its valuation anticipated to reach $15.57 million by 2030, driven by a compound annual growth rate (CAGR) of 5.5%. This projected growth during the forecast period can be primarily attributed to several factors, including an increase in inflammatory bowel disease cases, broader biologic reimbursement coverage, patients’ preference for less frequent dosing, the impact of biosimilar competition, and advancements in biologic delivery devices. Key trends for the upcoming period encompass the increasing application of targeted biologic therapies, the broadening of autoimmune disease indications, a transition towards long-term maintenance treatments, the rising uptake of subcutaneous biologics, and an increase in administration at home.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

Which Drivers Are Influencing Market Acceleration In The Stelara (Ustekinumab) Market?

An increasing number of individuals affected by psoriasis is anticipated to drive the expansion of the stelara (ustekinumab) market moving forward. Psoriasis patients are defined as those experiencing a chronic autoimmune condition characterized by accelerated skin cell regeneration, leading to the development of red, scaly patches. This growing prevalence of psoriasis sufferers can be attributed to multiple factors, including enhanced diagnostic methods, environmental triggers, inherited genetic factors, and an increasingly older demographic. stelara (ustekinumab) functions by targeting and inhibiting interleukin-12 and interleukin-23, thereby assisting psoriasis patients through effective reduction of inflammation and plaque development, which contributes to clearer skin and sustained symptom control, ultimately boosting their quality of life. For example, a report released by the National Psoriasis Foundation (NPF), a U.S.-based non-profit organization, indicated that in August 2024, psoriasis impacts approximately 3% of U.S. adults aged 20 and above, amounting to over 7 million individuals. Furthermore, it is estimated that about 600,000 adults within the nation suffer from psoriasis yet have not received a diagnosis. Consequently, the escalating prevalence of psoriasis patients is expected to stimulate the growth of the stelara (ustekinumab) market.

What Leading Segments Are Studied In The Stelara (Ustekinumab) Market?

The stelara (ustekinumab) market covered in this report is segmented –

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications

2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Pediatric, Adult, Geriatric

Which Trends Are Expected To Influence The Stelara (Ustekinumab) Market In The Upcoming Years?

Major companies engaged in the stelara (ustekinumab) market are developing innovative offerings, including biosimilars to stelara, to provide a cost-effective therapeutic choice for patients with chronic inflammatory ailments. Stelara biosimilars are biologically analogous drugs created to replicate the therapeutic benefits of Stelara (Ustekinumab), designed to target IL-12 and IL-23 for treating autoimmune conditions such as psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical organization, announced the U.S. Food and Drug Administration (FDA) approval for IMULDOSA (ustekinumab-srlf), which is a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is distinguished by its wide-ranging indications, offering treatment for adult patients suffering from moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. It also has a unique indication for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it highly adaptable across different age demographics. This extensive applicability establishes IMULDOSA as a valuable alternative for addressing various immune-mediated inflammatory diseases.

Which Key Players Are Driving Competition In The Stelara (Ustekinumab) Market?

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

Which Region Is Projected To Lead The Stelara (Ustekinumab) Market During The Forecast Period?

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Stelara (Ustekinumab) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19935&type=smp

Browse Through More Reports Similar to the Global Stelara (Ustekinumab) Market 2026, By The Business Research Company

Stevia Market Report 2026

https://www.thebusinessresearchcompany.com/report/stevia-global-market-report

Stearic Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/stearic-acid-global-market-report

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795